Norbert Gattermann

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Elsa Bernard, Heinz Tuechler, Peter L. Greenberg et al. · NEJM Evidence · 2022 · 813 citations · Full text

Medicine, Genetics, Hematology +16

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 745 citations · Full text

Medicine, Oncology, Pharmacology +9

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla et al. · Blood · 2010 · 379 citations

Pharmacy, Pharmacology, Pharmacotherapy +5

Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients

Ulrich Germing, Norbert Gattermann, Corinna Strupp et al. · Leukemia Research · 2000 · 296 citations

Medicine, Hematology, Internal Medicine +10